Dr. Pishvaian Discusses Progress in Pancreatic Cancer
In Partnership With:
Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.
Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.
There has been significant progress in the treatment of pancreatic cancer over the past 5 years, says Pishvaian. In his lecture during the symposium, he went over treatment options such as immunotherapy and local therapy.
Although immunotherapy has not yet shown significant results in pancreatic cancer, Pishvaian says that there is an interest in developing a strategy to optimize benefit.
